Eight-Week Bedaquiline-Linezolid Noninferior for TB
TUESDAY, Feb. 28, 2023 -- A strategy of eight weeks of bedaquiline-linezolid is noninferior to a standard regimen for tuberculosis, according to a study published online Feb. 20 in the New England Journal of Medicine to coincide with the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2023 Category: Pharmaceuticals Source Type: news
FDA Serotonin Syndrome Warning Unnecessary? FDA Serotonin Syndrome Warning Unnecessary?
Although the antibiotic linezolid carries a warning against its use by patients taking antidepressants, owing to risk for serotonin syndrome, new research suggests that that concern may be unnecessary.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - December 29, 2022 Category: Psychiatry Tags: Psychiatry News Source Type: news
Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
Conclusion: Oritavancin, used to support ED, is associated with lower costs compared with dalbavancin and reduced treatment duration relative to all comparators. Its use would support an ED approach in MRSA ABSSSI management. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news
Emergence of High Antimicrobial Resistance among Critically Ill Patients with Hospital-Acquired Infections in a Tertiary Care Hospital.
Conclusions: The current study describes the high antibiotic resistance patterns in various hospital units that need extra legislation to prevent healthcare providers from misprescription and overuse of antibiotics. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news
Bedaquiline - Pretomanid - Linezolid Regimens Compared for XDR TB
Overall risk - benefit ratio seems to favor patients receiving linezolid at dose of 600 mg for 26 weeks (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 16, 2022 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news
Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB
FRIDAY, Sept. 16, 2022 -- For patients with extensively drug-resistant (XDR) tuberculosis, the overall risk-benefit ratio seems to favor patients receiving the bedaquiline-pretomanid-linezolid regimen with linezolid at a dose of 600 mg for 26 weeks,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 16, 2022 Category: Pharmaceuticals Source Type: news
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 develo...
Source: Johnson and Johnson - August 17, 2022 Category: Pharmaceuticals Source Type: news
Linezolid Effective for Gram-Positive Bacterial Infections in ICU Linezolid Effective for Gram-Positive Bacterial Infections in ICU
Data from a real-world study of ICU patients showed linezolid ' s effectiveness as a first or second-line therapy.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 26, 2022 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news
Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis
Purpose: Neonatal sepsis (NS) has no specific clinical manifestations and blood culture analysis requires a long period of time. Knowledge of prevalent bacterial isolates and their antibiotic susceptibility is crucial when choosing an empirical therapy to decrease morbidity and mortality. This literature review summarizes the distribution characteristics and antimicrobial resistance of bacterial pathogens associated with bloodstream infections in Chinese neonates, and thus serves as a reference for pediatricians. Methods: The full-text journal database, CNKI, was searched using the key words " neonatal " , " sepsis " , and...
Source: Current Awareness Service for Health (CASH) - March 14, 2022 Category: Consumer Health News Source Type: news
linezolid
Title: linezolidCategory: MedicationsCreated: 3/3/2022 12:00:00 AMLast Editorial Review: 3/3/2022 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - March 3, 2022 Category: Drugs & Pharmacology Source Type: news
Infectious Disease Alert Updates
Sepsis Bundle Erodes Gains in Stewardship; Asymptomatic Transmission of COVID-19 in Households; When Is Hand Hygiene Personally Protective? Four different categories of antibiotic use were observed, including broad-spectrum antibiotics for community-acquired infection, broad-spectrum antibiotics for nosocomial infection/multidrug-resistant organisms, the use of anti-methicillin-resistant Staphylococcus aureus (MRSA) agents (such as vancomycin, daptomycin, linezolid, ceftaroline, etc.), as well as antibiotics for surgical prophylaxis. [...]a gap of up to 24 hours may occur before the physician picking up the case the next d...
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news
BPaL regimen can cut time for treatment of drug-resistant TB
BPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB Alliance developed antibiotic pretomanid, along with two other antibiotics: bedaquiline and linezolid. (Source: The Economic Times)
Source: The Economic Times - July 22, 2021 Category: Consumer Health News Source Type: news
Resistant TB: Adjustments to BPaL Regimen Reduce AEs, Not Efficacy Resistant TB: Adjustments to BPaL Regimen Reduce AEs, Not Efficacy
High success rates in tuberculosis treatment remain after lowering linezolid dose and duration to reduce toxic effects.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 19, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: A comprehensive review
Staphylococcus aureus is one of the leading hospital-associated and community-associated pathogens, which has caused a global public health concern. The emergence of methicillin-resistant S. aureus (MRSA) along with the widespread use of different classes of antibiotics has become a significant therapeutic challenge. Antibiotic resistance is a disturbing problem that poses a threat to humans. Treatment options for S. aureus resistant to β-lactam antibiotics include glycopeptide antibiotic, cyclic lipopeptide antibiotic, cephalosporins and oxazolidinone antibiotic. The most representative types of these antibiotics are van...
Source: Current Awareness Service for Health (CASH) - July 16, 2021 Category: Consumer Health News Source Type: news
Africa: Active TB Drug Safety Monitoring and Management (ADSM) Global Database - Outcome of the Assessment and Future of Data Reporting
[WHO] A global database set up by WHO's Global Tuberculosis Programme in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR) has been collating data on Active TB Drug Safety Monitoring and Management (aDSM) since 2016, to monitor the safety of patients who receive MDR-TB treatment with new medicines (e.g. bedaquiline, delamanid), repurposed medicines (e.g. linezolid, clofazimine) or new regimens, which don't have a well-established safety profile. The aDSM framework has (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - July 12, 2021 Category: Infectious Diseases Source Type: news
